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Cancer stem cells (CSCs) are a subpopulation of cancer cells that play a pivotal role in 
tumor development, invasion, metastasis, and recurrence. We and others have reported 
significant involvement of the NF-κB pathway in regulating CSCs of non-small cell lung 
cancer (NSCLC). In this study, we evaluated the effects of NF-κB inhibition on self-renewal, 
stemness, migration, and expression of genes involved in the epithelial to mesenchymal 
transition (EMT) and apoptosis resistance in lung CSCs. Different concentrations of the 
NF-κB inhibitor BMS-345541 (0.4, 4.0, and 10.0 µM), an inhibitor the NF-κB upstream 
kinase IKKβ, were used to treat both lung CSCs (CD166+CD44+, CD166+EpCAM+) and 
non-CSC NSCLC cells (CD166−CD44−, CD166−EpCAM−) in A549 and H2170 cell lines. 
We assessed the impact of BMS-345541 on the ability to form tumorspheres (self-re-
newal assay), expression of stemness genes (SOX2, OCT4, NANOG, SCA-1, and KLF4), 
migration, and expression of EMT and apoptosis-related genes. Inhibition of NF-κB by 
BMS-345541 effectively reduced the stemness, self-renewal, and migration capacity 
of lung CSCs. Moreover, expression of genes involved in the EMT (SNAI1 and TWIST) 
and apoptosis resistance (BCL-2, BAX, and BIRC5) was significantly reduced following 
the treatments, suggesting that NF-κB inhibition is sufficient to prevent the EMT and 
induce apoptosis in lung CSCs. Our findings suggest that NF-κB inhibition could reduce 
the capability of CSCs to maintain their population within the tumor mass, potentially 
decelerating cancer progression, relapse, and chemotherapy resistance.
Keywords: nF-κB signaling, lung cancer, cancer stem cells, cancer migration, self-renewal
inTrODUcTiOn
Emerging evidence suggests the presence of a subpopulation within tumors with the abilities to self-
renew and to produce differentiated progeny. This subpopulation of cells, known as cancer-initiating 
cells or cancer stem cells (CSCs) (1), was first characterized in 1994 in leukemia (2). Their presence 
was later confirmed in many human carcinomas, including breast, brain, colon, and lung cancers 
(3–7). CSCs play a pivotal role in tumor development, invasion, metastasis, drug resistance, and 
recurrence (8). Previously, we isolated and characterized putative CSCs from non-small cell 
TaBle 1 | List of antibodies used in cancer stem cells isolation.
antibody clone isotype Manufacture
CD166 3A4 Mouse IgG1, κ BD Biosciences, San Jose, CA, USA
CD44 L178 Mouse IgG1, κ BD Biosciences, San Jose, CA, USA
EpCAM 158206 Mouse IgG1, κ R&D System, Minneapolis, MN, USA
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lung cancer (NSCLC) cell lines based on expression of specific 
cell surface markers (i.e., CD166, CD44, and EpCAM) (9). 
CSCs that were isolated based on the expression of combined 
CD166+/CD44+ and CD166+/EpCAM+ exhibited stemness 
in vitro and were able to form secondary tumors in vivo. The 
transcriptomic analysis of these populations of cells revealed 
a significant involvement of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) in regulating the putative 
lung CSCs.
The NF-κB family consists of five proteins: p65 (RelA), 
RelB, c-Rel, NF-κB1 (p105/p50), and NF-κB2 (p100/p52) 
(10, 11). These NF-κB proteins share a conserved N-terminal 
Rel homology domain, which enables nuclear translocation, 
DNA binding, and formation of homo- and heterodimers 
(10, 11). NF-κB proteins are expressed in the cytoplasm of 
most cell types, including differentiated cells, stem cells, and 
cancer cells (12, 13). In the inactive form, NF-κB homo- and 
heterodimers are bound to inhibitory IκB proteins (14) that 
mask the nuclear localization sequences (14). Activation of 
canonical pathways can be induced by many stimuli, includ-
ing lipopolysaccharide and pro-inflammatory growth factors 
and cytokines [e.g., tumor necrosis factor alpha (TNF-α) or 
interleukin-1] (15). Upon activation, the IkB kinase (IKK) 
complex (IKKα, IKKβ, and IKKγ) phosphorylates the inhibi-
tor IκB proteins at serine residues (e.g., 32 and 36 in IκBβ) 
and leads to their proteasomal degradation. Subsequent 
nuclear translocation of NF-κB and binding to its consensus 
sequences activate transcription of the respective target genes 
that regulate cellular proliferation, migration, and preventing 
apoptosis process.
Although aberrant NF-κB signaling has been associated with 
development and progression of various cancers, there is no 
detailed knowledge about the effect of this pathway on CSCs in 
lung cancer. In this study, the impact of NF-κB inhibition on the 
expression of genes associated with stemness, migration, and 
apoptosis of putative lung CSCs was evaluated. In addition, the 
effects of the NF-κB inhibitor BMS-345541 on the formation 
of tumorspheres (self-renewal) were also assessed. Finally, the 
influence of the blockade of NF-κB-mediated signaling on the 
migratory behavior of lung CSCs was evaluated using scratch-
wound healing assay.
MaTerials anD MeThODs
Materials and cell lines
BMS-345541 purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Cell lines A547 (human lung carcinoma) and H2170 
(human lung squamous cell carcinoma) purchased from the 
American Type Culture Collection (ATCC, Manassas, VA, 
USA).
cell culture
All cells were cultured in RPMI-1640 medium (Gibco, Life 
Technologies, Foster City, CA, USA) supplemented with 
10% fetal bovine serum (FBS) (Gibco) and 1% penicillin/
streptomycin (Gibco) in a humidified incubator at 37°C and 
5% CO2.
isolation and characterization of Putative 
lung cscs
The putative lung CSCs and non-CSCs used in this study were 
isolated based on expression of specific CSCs markers (CD166, 
CD44, and EpCAM) (9, 16). Cells were detached with trypsin 
(Life Technologies, Carlsbad, CA, USA) and washed with phos-
phate buffer solution (PBS) containing 2% FBS (PBS with 2% 
FBS). A total of 1 × 107 cells were incubated for 30 min (on ice and 
in the dark) with respective antibodies (Table 1). The unbound 
antibodies were washed away with PBS with 2% FBS through 
centrifugation. Prior to sorting, the labeled cell suspensions 
were filtered through a 40-µm cell strainer to obtain a single cell 
suspension. The labeled cells were sorted into CD166+/CD44+, 
CD166−/CD44−, CD166+/EpCAM+, and CD166−/EpCAM− 
subsets using a fluorescence activated cell sorter (FACSAriaII, 
Becton Dickinson, Franklin Lakes, NJ, USA).
Quantitative real-Time Polymerase chain 
reaction (qrT-Pcr)
Total RNA was extracted from approximately 1  ×  106 cells 
using a Qiagen AllPrep RNA isolation kit (Qiagen, Limburg, 
Netherlands) according to the manufacturer’s instructions. 
The concentration and purity of the extracted RNA were 
determined using Nanodrop (Agilent Technologies, Santa 
Clara, CA, USA). The RNA samples were stored at −80°C for 
later use. Complementary DNA (cDNA) was synthesized from 
3 µg of total RNA using the Transcriptor High Fidelity cDNA 
Synthesis Kit (Roche Applied Science, Mannheim, Germany) 
using a random hexamer primer and an anchored-oligo (dT) 
primer. Expression of selected genes was analyzed using an ABI 
StepOnePlus™ Real-Time PCR machine (Applied Biosystems, 
Foster City, CA, USA). The qPCR reaction was prepared using 
a Taqman® gene expression assay (Applied Biosystems) and the 
primers listed in Table 2.
sphere assay
The effect of NF-κB inhibition on CSC self-renewal was evalu-
ated using a sphere assay. All cells (parental, CSCs, and non-
CSCs of A549 and H2170 cell lines) were treated with different 
concentrations (0, 0.4, 4.0, and 10.0  µM) of BMS-345541 for 
24 and 48  h. After each respective time point, the cells were 
trypsinized and 1.0 × 103 cells/ml were cultured in 24-well ultra-
low attachment plates (Corning, Corning, NY, USA) containing 
serum-free medium DMEM/F12 (Gibco) supplemented with 
TaBle 2 | List of Taqman® gene expression primers.
accession number gene symbol amplicon length 
(base pairs)
Hs01023894_m1 E-cadherin 61
Hs00983056_m1 N-cadherin 66
Hs00958111_m1 Vimentin 65
Hs00195591_m1 SNAI1 66
Hs02379973_s1 TWIST1 154
Hs01053049_s1 SOX2 91
Hs00999632_g1 OCT4 77
Hs04399610_g1 NANOG 101
Hs00358836_m1 KLF4 110
Hs00165656_m1 SCA-1 97
Hs00900055_m1 VEGFA 59
Hs00765553_m1 CCDN1 57
Hs00608023_m1 BCL-2 81
Hs00180269_m1 BAX 62
Hs04194392_s1 BIRC5 102
Hs02758991_g1 GAPDH 93
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10 ng/ml fibroblast growth factor, 1% of B27 (optimized serum-
free supplement), 20 ng/ml of epidermal growth factor, and 1% 
penicillin–streptomycin (all purchased from Invitrogen). Sphere 
size was assessed after 14  days. The sphere size was assessed 
by measuring the diameter (µM) of each formed spheres using 
ImageJ software.
Migration assay
Sorted and parental NSCLC cells were seeded at a density of 
3–4 × 105 cells/well in complete medium and grown overnight 
to a confluence of 90%. Subsequently, the cells were treated with 
colcemide (10  µg/ml) for 2  h. After incubation, a scratch was 
inflicted using a sterile 200  µl pipette tip, and gentle washing 
was carried out twice using PBS to remove debris. The cells were 
incubated with 1 ml of medium containing different concentra-
tions of BMS-345541 for 24 and 48 h. Images of wound coverage 
were captured at ×10 magnification (Olympus IX 71; Olympus, 
Tokyo, Japan) at 0, 24, and 48 h. The coverage area was measured 
using ImageJ and the percentage of the migrated distance was 
calculated as:
 
Percentage of coverage area
area after 24 48h initial are
=
( / ÷ a at h 10 00) .×  
statistical analysis
All data were expressed as the mean ± SD of three independent 
experiments. Comparison between treatment groups with the 
untreated group was performed using two-way analysis of vari-
ance (SPSS statistical package). p-Values of <0.05 were considered 
to be statistically significant.
resUlTs
inhibition of nF-κB reduces the 
expression levels of stemness genes
Cancer stem cells from NSCLC lines (A549 and H2170) were 
isolated based on expression of surface markers CD166, 
CD44, and EpCAM. The isolated CSCs (A549 CD166+CD44+, 
A549 CD166+EpCAM+, and H2170 CD166+EpCAM+) and 
their non-CSC counterparts (A549 CD166−CD44−, A549 
CD166−EpCAM−, and H2170 CD166−EpCAM−) were treated 
with 0.4, 4.0, and 10.0  µM BMS-345541. The effect of the 
treatment was first evaluated by measuring the expression of 
stem cell transcription factors SOX2, NANOG, OCT4, SCA-
1, and KLF4 for both cell cancer and non-CSC populations 
(Figures  1A–F). Treatment with all concentrations of BMS-
345541 for 48  h reduced the expression of SOX2, NANOG, 
OCT4, and SCA-1 in A549 CD166+CD44+ cells. However, 
expression levels of the genes remained unaltered in the A549 
CD166−CD44− subpopulation except for SCA-1 and KLF-4. In 
A549 CD166+EpCAM+ cells, the expression levels of SOX2, 
NANOG, and OCT4 were reduced following treatment with 
0.4, 4.0, and 10.0  µM BMS-345541. In the non-CSC sub-
population A549 CD166−EpCAM−, 10.0 µM BMS-345541 was 
needed to reduce the expression of SOX2 and SCA-1. In H2170 
CD166+EpCAM+ cells and the non-CSCs subpopulation 
(H2170 CD166−EpCAM−), treatment with 10.0  µM reduced 
the expression of SOX2 and KLF4 in the cells.
nF-κB inhibits the expression of genes 
involved in the epithelial to Mesenchymal 
Transition (eMT)
Activation of NF-κB is involved in several important processes 
in cancer, including regulating the expression of EMT tran-
scription factors (17), inducing apoptosis resistance (18), and 
regulating the angiogenesis and proliferation of cancer cells. The 
effectiveness of the NF-κB inhibitor BMS-345441 in targeting 
lung CSCs was evaluated by its ability to reduce the expression of 
genes involved in those processes. Treatment with 0.4, 4.0, and 
10.0 µM BMS-345441 did not exert any effect on expression of 
SNAI1 and TWIST1 (Figure 2A), and expression levels of mes-
enchymal markers N-cadherin and Vimentin and the epithelial 
marker E-cadherin were unchanged in A549 CD166+CD44+ 
cells (Figure 2B). Treatment with 10.0 µM BMS-345441 down-
regulated the expression of TWIST1, Vimentin, and E-cadherin 
in A549 CD166+EpCAM+ cells when treated for 24 and 48  h 
(Figures 2C,D). However, treatment of the cells with the same 
concentration of BMS-345441 increased expression of SNAI1 
when the treatment was prolonged to 48 h, but expression of 
N-cadherin was unchanged. In H2170 CD166+EpCAM+ cells, 
prolonged treatment with BMS-345541 for up to 48 h increased 
the expression of SNAI1 (treatment with 10.0 µM) but increased 
the expression of TWIST1 (treatment with 0.4, 4.0, and 10.0 µM) 
(Figure  2E). Expression of N-cadherin remained unchanged 
but expression of Vimentin increased following prolonged 
treatment, indicating that its expression is regulated by SNAI1 
(Figure 2F).
BMS-345441 treatment also affected the expression of 
EMT genes in non-CSCs. In A549 CD166−CD44− cells, 
treatment with 4.0 and 10.0 µM BMS-345441 at 24 and 48 h 
slightly reduced the expression of TWIST1, but prolonged 
treatments increased the expression of SNAI1 (Figure  2G). 
However, treatment did not have a significant effect on the 
FigUre 1 | Effect of BMS-345541 on expression of stem cell transcription factors in lung cancer stem cells (CSCs). The graphs show the relative expression of 
stemness genes SOX2, NANOG, OCT4, SCA-1, and KLF4 in (a–c) lung CSC and (D–F) non-CSC populations. The fold change was calculated using the 2−ΔΔct 
formula, and GAPDH was used as the internal control. Graphs show fold change relative to the untreated sample. The results represent the mean ± SD of three 
replicates. The p-value was calculated using analysis of variance by comparing the treatment groups with the untreated group (*p < 0.05).
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expression of N-cadherin, Vimentin, and E-cadherin at both 
time point except for the expression of E-cadherin when 
treated with 10 µM BMS-345441 for 24 h (Figure 2H). In A549 
CD166−EpCAM− cells, treatment with 10.0 µM BMS-345441 
for 48  h increased the expression of SNAI1 and TWIST1 
(Figure 2I) and N-cadherin, but expression of Vimentin and 
E-cadherin were only slightly changed (Figure 2J). In H2170 
CD166−EpCAM− cells, treatment with 4.0 and 10.0  µM 
increased expression of SNAI1, TWIST1, N-cadherin, and 
Vimentin, but expression of E-cadherin was decreased 
(Figures 2K,L).
nF-κB inhibits the expression of genes 
involved in the apoptosis resistance 
Process
The NF-κB pathway is involved in apoptosis resistance through 
activation of anti-apoptotic genes, including BCL-2 and BIRC5. 
FigUre 2 | Quantitative real-time polymerase chain reaction results showing expression of genes involved in the epithelial to mesenchymal transition (EMT) process 
in lung cancer stem cells treated with different concentrations of BMS-345441. Relative expression of EMT switch genes (SNAI1 and TWIST1), mesenchymal 
markers (N-cadherin and Vimentin), and the epithelial marker (E-cadherin) in (a,B) A549 CD166+CD44+; (c,D) A549 CD166+EpCAM+; (e,F) H2170 
CD166+EpCAM+; (g,h) A549 CD166−CD44−; (i,J) A549 CD166−EpCAM−; and (K,l) H2170 CD166−EpCAM− cells. The fold change was calculated using the 2−ΔΔct 
formula, and GAPDH was used as the internal control. Graphs show fold change relative to the untreated sample. The results represent the mean ± SD of three 
replicates. The p-value was calculated using analysis of variance by comparing the treatment groups with the untreated group (*p < 0.05).
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FigUre 3 | Expression of pro-apoptotic genes (BCL-2 and BIRC5) and the anti-apoptotic gene BAX in lung cancer stem cells following treatment with different 
concentrations of BMS-345541. Relative expression of BCL2, BAX, and BIRC5 in (a) A549 CD166+CD44+; (B) A549 CD166+EpCAM+; (c) H2170 CD166+EpCAM+; 
(D) A549 CD166−CD44−; (e) A549 CD166−EpCAM−; and (F) H2170 CD166−EpCAM− cells. The fold change was calculated using the 2−ΔΔct formula, and GAPDH 
was used as the internal control. The results represent the mean ± SD of three replicates. The p-value was calculated using analysis of variance by comparing the 
treatment groups with the untreated group (*p < 0.05).
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Expression levels of BCL2, BAX, and BIRC5 in A549 CD166+CD44+ 
cells were downregulated when treated with 4.0 µM BMS-345541 
for 24  h (Figure  3A). However, expression levels of BCL2, BAX, 
and BIRC5 were unchanged when treated with 0.4 and 10.0  µM 
BMS-345441 compared to the untreated control. Expression of 
BCL2 and BAX in A549 CD166+EpCAM+ cells treated with 10.0 µM 
BMS-345541 for 24 h was downregulated (Figure 3B). Prolonged 
treatment of the cells for up to 48 h led to increased expression of all 
three genes. Treatment with BMS-345441 reduced the expression 
of BCL2 and BAX in H2170 CD166+EpCAM+ cells treated with 
10.0 µM for 24 and 48 h (Figure 3C). In the three non-CSC subpopu-
lations, treatment with 10.0 µM BMS-345441 was the most effective 
at inducing downregulation of BCL2 and BAX (Figures  3D–F). 
Expression of BIRC5 in the cells remained unchanged following 
FigUre 4 | Continued
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treatments with BMS-345441, except for A549 CD166−CD44− cells, 
for which treatment with 10.0 µM BMS-345441 significantly down-
regulated expression of the gene (p = 0.035).
nF-κB inhibition reduces self-renewal 
capability of Parental and lung cscs
Self-renewal is an important characteristic of CSCs that helps 
maintain the CSC pool in the tumor. Therefore, the effectiveness 
of the NF-κB inhibitor BMS-345541 in targeting lung CSCs can 
be assessed by looking at its ability to reduce the sphere-forming 
capacity of lung CSCs. Following treatment with different con-
centrations of BMS-345441 for 24 or 48 h, the cells were induced 
to form spheres by culturing in sphere-forming medium. After 
14 days, the diameter of formed spheres was measured. Regardless 
of the treatment status, both CSC and non-CSC populations had 
the ability to form spheres (Figure  4A). Treatment with BMS-
345441 significantly reduced the sphere size of lung CSCs and non-
CSCs in a concentration and time-dependent manner. Treatment 
with 0.4, 4.0, and 10.0 µM BMS-345441 for 24 h reduced the size 
of the spheres of A549 CD166+CD44+ cells (Figure 4B). For A549 
CD166+EpCAM+ and H2170 CD166+EpCAM+ cells, the sphere 
size was reduced after treatment with 0.4, 4.0, and 10.0 µM BMS-
345541 at 24 and 48 h (Figure 4B). The sphere size of non-CSCs 
was also reduced following treatment with different concentra-
tions of BMS-345441 at different time points (Figure 4B).
FigUre 4 | Effect of BMS-345541 on the sphere-forming capacity of lung cancer stem cells (CSCs). The cells were induced to form sphere following treatment 
with different concentrations of BMS-345541 for 24 and 48 h. (a) The images of the spheres formed following the treatments with BMS-345441 for lung CSCs and 
non-CSC counterparts. (B) Boxplots illustrate the sphere diameter (μm) for each cell type following the treatments. Data shown are representative of three 
independent experiments (n = 3). The y-axes show the sphere diameter (μm) and the x-axes show the concentration of BMS-345441 (0, 0.4, 4.0, and 10.0 µM) 
used in the treatment. Upper and lower boxplot margins represent the interquartile range, and the middle bar indicates the median. The whisker defines the range of 
values. The diameter of the spheres was measured using ImageJ analysis software. The bar above the boxes represents statistically significant differences 
*p < 0.05; two-way analysis of variance.
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nF-κB inhibits the Migration of lung cscs
The migration assay was performed to determine the effect of the 
NF-κB inhibitor BMS-345541 in inhibiting the migration of lung 
CSCs and non-CSCs. Figure 5 shows images of the scratch-wound 
healing assay and the graph illustrating the percentage of wound 
closure. Treatment with 0.4, 4.0, and 10.0 µM BMS-345441 was 
effective in inhibiting the migration of A549 CD166+EpCAM+ 
(except 4.0 µM at 48 h) and H2170 CD166+EpCAM+ cells at 24 
and 48 h. However, only treatment with 10.0 µM alone reduced 
the migration of A549 CD166+CD44+ cells when treated for 24 
and 48 h. The migration of all three non-CSCs was inhibited by 
treatment with 4.0 and 10.0 µM, but the effect was time depend-
ent. Taken together, these results show that higher concentration 
of BMS-345441 (10.0 µM) effectively inhibited the migration of 
CSCs and non-CSCs.
DiscUssiOn
The presence of CSCs population in lung tumor is the key to 
treatment failure (19). This cell having the ability to self-renew 
and differentiate, which is the key to chemotherapy resistance 
thus makes it very difficult to eliminate the CSCs (20). NF-κB 
activation has been associated with the initiation and progression 
of several human cancers, including breast, cervical, prostate, 
pancreatic, and lung cancer (21–23). In lung cancer, a high level of 
NF-κB activity was detected in patients with SCLC and NSCLC, 
and its constitutive activity was associated with advanced stage 
and poor prognosis of patients (22, 24). Gene expression and 
bioinformatics result from our previous study demonstrated that 
NF-κB was highly associated with the CSCs gene signature (9) 
and inhibition NF-κB might resulted in reduction of the lung 
CSCs stemness and tumorigenic properties. The NF-κB molecule 
is regulated by the IKK complex (23, 25, 26), hence became the 
most suitable candidate for a therapeutic target for cancer treat-
ments (27). BMS-345541, an IKK complex inhibitor, has been 
used to deactivate of NF-κB in various types of cancer, including 
melanoma and leukemia (28, 29). BMS-345541 at a concentration 
as low as 0.4 µM and up to 10.0 µM effectively inhibited activity 
of NF-κB (28–31). Therefore, in our study, BMS-345441 at three 
different concentrations (0.4, 4.0, and 10.0 µM) was used to treat 
lung CSCs, and the effects were evaluated against the expression 
of stemness, EMT and apoptosis genes, sphere-forming capabil-
ity, and migration. The results indicate that BMS-345441 shows 
promising results in reducing sphere size, expression of stemness 
genes, and migration of lung CSCs as well as parental cancer 
cells. Moreover, expression of genes related to EMT and apop-
tosis was reduced following treatment, suggesting that inhibiting 
the NF-κB expression may help preventing EMT activities and 
induce apoptosis of lung CSCs.
Activation of NF-κB is one of the mechanisms that mediates 
self-renewal of CSCs (32, 33). Self-renewal is one of the main 
features of CSCs that helps maintain CSCs population in tumor. 
FigUre 5 | Continued
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FigUre 5 | Effect of BMS-345541 on the migration of lung cancer stem cells of A549 and H2170 cells. Scratches were made and the cells were treated with 
different concentrations of BMS-345541. (a) Images of the wound area were taken at 0, 24, and 48 h after treatment. The wound areas were measured using 
ImageJ analysis software. (B) Percentage of migrated area [(area after 24/48 h ÷ initial area at 0 h) × 100%]. Data shown are representative of three independent 
experiments (n = 3). The p-value was calculated using analysis of variance by comparing the percentage of wound area for each treatment with that of the untreated 
group (*p < 0.05).
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The effectiveness of NF-κB inhibition in targeting lung CSCs is 
evidence by the reduction of sphere-forming capacity of lung 
CSCs and non-CSCs. The ability to reduce the sphere-forming 
capacity reflects the self-renewal capability of those cells. Our 
finding is in parallel with reports for other types of cancer. For 
instance, inhibition of NF-κB using the plant-derived agent 
Triptolide reduced the colony- and sphere-forming capacity of 
pancreatic CSCs (34). Xiang et al. reported that NF-κB induced 
self-renewal of CD133+ ovarian CSCs and its inhibition has 
reduced the self-renewal capability of the cells (35).
Expression of several stemness genes, including SOX2, OCT4, 
KLF4, and NANOG, is an important indicator for the multipotent 
characteristic of CSCs (9, 36). Our study demonstrated that inhi-
bition of NF-κB reduced the expression of stem cell transcription 
factors SOX2, NANOG, and OCT4 in CSCs of A549 cells and 
expression of SOX2, SCA-1, and KLF4 in CSCs of H2170 cells. 
The roles of transcription factors in maintaining the stemness 
and tumourigenicity state of the CSCs have been reported previ-
ously. For example, SOX2, OCT4, and NANOG were found to be 
overexpressed in several cancers, including breast, prostate, and 
oral squamous cell carcinoma, and their expression levels were 
associated with tumor transformation, tumourigenicity, and 
tumor metastasis (37–39). Unlike in embryonic stem cells where 
these transcription factors mostly control differentiation of the 
cells, overexpression of SOX2, OCT4, and NANOG in CSCs was 
reported to modulate signaling pathways involved in the inhibit-
ing apoptosis (40, 41). Therefore, reduction in the expression of 
these transcription factors indicates that the cells have lost their 
multipotent characteristics, including the self-renewal capability, 
and the reduction also likely induces apoptosis of the cells. The 
effect of NF-κB in regulating the expression of stemness genes 
was not consistent in every cell, which indicates differently 
response to the treatments. This is likely due to the heterogeneous 
population of CSCs as a result from asymmetric division which 
generates diversity within the cancer (42). NF-κB activation has 
been associated with invasive and metastatic capabilities of can-
cer and CSCs. The cancer cells invasion and metastasis process 
occur when the epithelial cancer cells loss its adherent properties 
and acquire the mesenchymal phenotype which then allow the 
cells to migrate (43, 44). This process is known as EMT. EMT 
process is activated by transcription of its genes including SNAI1 
(45, 46), TWIST1 (47, 48), Slug, and ZEB1/2 (49) [reviewed in 
Ref. (17)] and its activation is demonstrated by the loss of epi-
thelial marker (E-cadherin) expression and gain of mesenchymal 
marker (Vimentin and N-cadherin) expression (49, 50). The roles 
of the EMT in CSCs and cancer cell migration and metastasis 
suggesting that inhibiting the EMT process could result in reduc-
ing migration and metastatic potential of CSCs. Our results 
demonstrated that the migration capability of CSCs was reduced 
following the treatment with IKK kinase inhibitor, BMS-345541. 
This finding was in agreement with previous finding in NSCLC 
where inhibition of NF-κB has resulted in suppression of EMT 
transcription factors TWIST1, SNAI1, Slug, and ZEB2 and 
prevented the invasion and metastasis of the cells (51). Although 
our migration data show that NF-κB inhibition have significantly 
reduced CSCs migration, the expression of EMT genes was not 
in agreement with the data.
The gene expression data demonstrated that BMS-345541 
treatment reduced the expression of TWIST1 in lung CSCs 
populations A549 CD166+CD44+, A549 CD166+EpCAM+, and 
H2170 CD166+EpCAM+but increased the expression of SNAI1 
in A549 CD166+EpCAM+ and H2170 CD166+EpCAM+ cells. 
The same result was seen in the non-CSC populations A549 
CD166−EpCAM− and H2170 CD166−EpCAM−. Although both 
SNAI1 and TWIST1 control activation of the EMT process, these 
genes are activated through different pathways. SNAIL family 
genes are activated through the NF-κB pathway, but TWIST 
family genes are activated through the Ras/Raf/ERK pathway 
(52, 53). SNAI1 upregulation via NF-κB occurs through phos-
phorylation of IKKα, which then activates NF-κB/p65 dimer 
and stimulates transcription of SNAIL (54). TheBMS-345541 
molecule is specifically targets the IKKβ subunit of the IKK 
complex, the IKKα subunit remain free to undergo phospho-
rylation, activate the NF-κB/p65 dimer and increase SNAIL 
expression. However, the upregulation of SNAIL alone is not 
enough to activate the EMT because its activation is controlled 
by sequential activation of several activators, including TWIST, 
ZEB, and Slug (53).
The NF-κB activation also involved in apoptosis resistance 
in cancer cells (28). This event occurs through overexpres-
sion of anti-apoptotic genes (14). The anti-apoptotic proteins 
include BCL-2, BCL-XL, and MCL-1, and BIRC5 whereas the 
pro-apoptotic proteins include BAX and BAK as well as the BH3 
domain molecules (e.g., Bid, Bim, Bik, Noxa, and Puma) (55). In 
our study, inhibition of NF-κB downregulated expression of the 
anti-apoptotic genes BCL-2 and BIRC5. Deactivation of NF-κB 
was reported to be associated with downregulation of BCL-2 
via a mechanism of caspase-3 activation that mediates BCL-2 
cleavage that later induces apoptosis activity (29). BMS-345541 
in the low micromolar range (1–2  µM/l) has been reported to 
induce apoptosis in leukemia cells (56). A higher concentration 
(10.0 µM) of BMS-345541 was found to induce apoptosis of mela-
noma cells (28). A lower concentration (2–5 µM) also resulted in 
induction of a moderate pro-apoptotic effect (28). The ability of 
BMS-345541 to induce apoptosis was also seen in combination 
with TNF-α (28).
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cOnclUsiOn
Results of this study indicate that NF-κB is a promising molecular 
target for lung CSCs, as the deactivation of NF-κB using the 
kinase inhibitor BMS-345541 effectively reduced the stemness, 
self-renewal, and migratory capabilities of lung CSCs. These 
effects limited the capability of CSCs to maintain their popula-
tion, and in theory this treatment might reduce cancer resistance 
to therapy and limit cancer progression. This finding may be a 
key to solving some major challenges in cancer therapy, namely 
cancer relapse and chemotherapy resistance, by eliminating 
CSCs. Future studies are needed to further elucidate the molecu-
lar machinery responsible for the effects of the inhibitor and to 
determine how it effects on other pathways that regulating cancer 
and normal stem cells. The cytotoxicity of the kinase inhibitor 
also must be evaluated specifically in lung cancer patient samples 
because it may have an unknown adverse effect. BMS-345541 has 
the potential to be developed into a specific anti-CSC therapy, 
but its use alone did not show consistent effects in targeting all 
different phenotypes of lung CSCs.
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